ABSTRACT
Presentamos un caso de hematuria masiva por fístula arterio-ureteral debido a complicación urológica de la cirugía vascular protésica. Este tipo de fístulas son una causa rara de hematuria macroscópica masiva y la presentación clínica más común es la hematuria intermitente. El diagnóstico es difícil y debe sospecharse clínicamente, siendo la confirmación mediante pruebas de imagen. La única posibilidad terapéutica es quirúrgica
We present a case of massive hematuria from artery-ureteral fistula due to urologic complication of the protesic vascular surgery. These kinds of fistula are a rare case of massive macroscopic hematuria and the commonest clinical presentation is the intermittent hematuria. The only therapeutic possibility is surgical
Subject(s)
Male , Aged , Humans , Hematuria/complications , Hematuria/diagnosis , Fistula/complications , Fistula/diagnosis , Urography/methods , Angiography/methods , Tomography, Emission-Computed/methods , Prostatic Hyperplasia/complications , Prostatic Hyperplasia/diagnosis , Urinary Bladder Fistula/diagnosis , Urography/trends , Urography , Angiography/trends , Angiography , Prostatic Hyperplasia/pathology , Prostatic HyperplasiaABSTRACT
We present a case of massive hematuria from artery-ureteral fistula due to urologic complication of the protesic vascular surgery. These kinds of fistula are a rare case of massive macroscopic hematuria and the commonest clinical presentation is the intermittent hematuria. The only therapeutic possibility is surgical.
Subject(s)
Hematuria/etiology , Iliac Artery , Ureteral Diseases/complications , Urinary Fistula/complications , Vascular Fistula/complications , Aged , Aged, 80 and over , Humans , MaleABSTRACT
OBJECTIVES: Herein we present the final results of a prospective randomized study comparing two prophylactic treatment modalities for superficial bladder tumors: chemotherapy with mitomycin C and immunotherapy with interferon. METHODS: The study comprised 65 patients. Mitomycin C was utilized in 34 and interferon in 31 patients. RESULTS: The mitomycin C-treated patients had 41% recurrence, 1.7 recurrence/100 patients-month, 17 months mean time to recurrence and 8.8% tumor progression. The patients receiving interferon had 45% recurrence, 2.4 recurrence/100 patients-month, 12 months mean time to recurrence and 22.2% tumor progression rate. No significant differences were observed between the two groups of patients. Treatment was well-tolerated by both groups and the cost:efficacy ratio was higher for the interferon-treated patients. CONCLUSIONS: Immunoprophylaxis with interferon is as effective, but costs more than chemoprophylaxis with mitomycin C. Both agents have a moderate effect relative to control of recurrence, time to recurrence and tumor progression.
Subject(s)
Interferon-alpha/therapeutic use , Mitomycin/therapeutic use , Neoplasm Recurrence, Local/prevention & control , Urinary Bladder Neoplasms/prevention & control , Adult , Aged , Aged, 80 and over , Humans , Interferon alpha-2 , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Prospective Studies , Recombinant ProteinsABSTRACT
Over the last decade, the evolution in the methods for imaging diagnosis incorporated to the clinical routine, has contributed to improve the prognosis of renal adenocarcinoma by making available an early diagnosis. Eighty-eight kidney tumours, of which 36 were diagnosed and treated between January 1976 and December 1984, and the other 52 between January 1985 and December 1992 are analyzed. The percentage of accidental diagnoses shifted from 8% to 29%. Decreased number of tumours diagnosed by their metastasis, from 22% to 6%. Increased percentage of cases diagnosed in early stages P1-P2, from 23% to 46%.
Subject(s)
Adenocarcinoma/diagnosis , Kidney Neoplasms/diagnosis , Adult , Aged , Female , Humans , Male , Middle Aged , Prognosis , Time FactorsABSTRACT
PSA is, currently, the best marker to detect prostatic changes, although it looses specificity when used in the differential diagnosis of certain pathologies of the prostate gland. Forty-four patients with benign prostate hyperplasia were analyzed and 26 (59%) of them were found to have higher than normal PSA levels. An estimate was made of the degree of correlation between serum PSA and prostatic volume in the patients examined, so as to find a formula that could be useful to apply this marker in the differential diagnoses of prostate adenoma and hidden prostate cancer. No linear relationship was found between prostate volume with benign hyperplasia and PSA (R = 0.13). This lack of relationship in a high percentage of patients with prostate adenoma induces to turn unnecessary to histopathological confirmation in order to rule out prostate cancer.
Subject(s)
Prostate-Specific Antigen/blood , Prostate/pathology , Prostatic Hyperplasia/blood , Prostatic Hyperplasia/pathology , Humans , Linear Models , MaleABSTRACT
By definition, the term paraganglioma includes all the tumours deriving from the body's paraganglion system, which are therefore ranked as intra-adrenal (pheochromocytoma) and extra-adrenal or paraganglion. Vesical paraganglion represents about 10% of all extra-adrenal paraganglioma and can be functional and non-functional. When functional, the symptoms are those originated from the products synthesised in excess, usually occurring in a paroxismical fashion, in relation with urination, ejaculation and defecation. Contribution of one vesical paraganglioma accidentally found in a 71 year-old female patients undergoing tests to study the extent of a right kidney carcinosarcoma.
